Recommended Free Tools
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
A mirror-image protein can reveal which molecules in an existing chemical collection might bind its opposite-handed counterpart—without first making thousands of mirror-image compounds. In a 2016 proof of concept, researchers used synthetic mirror-image MDM2 to screen 22,293 natural products and derivatives, then synthesized a mirror-image version of a hit. That compound inhibited the natural MDM2–p53 interaction in biochemical assays, but it was an early research lead, not a cancer treatment.
What makes a mirror-image chemical library “virtual”?
Many biological molecules are chiral: their atoms can be arranged in left- and right-handed forms, much like a pair of gloves. A protein made with the opposite handedness can recognize chiral molecules differently from the natural protein. That difference creates a way to search for compounds in a mirror-image chemical space that researchers have not physically assembled.
The method uses a mirror-image target protein as a proxy. A researcher screens ordinary compounds against the mirror-image protein, identifies promising binders, and then synthesizes selected mirror-image versions of those compounds to test against the natural protein. The library is “virtual” because the complete mirror-image collection is represented indirectly by screening its available counterparts; it is not a physical collection of thousands of synthesized mirror-image molecules.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
In their 2016 paper, the authors described using “two chemical syntheses of mirror-image substances including a target protein and hit compound(s)” to pursue lead discovery without making numerous mirror-image compounds. The key practical point is that synthesis is still required—for the mirror-image target and for selected mirror-image hits—but not necessarily for every compound in the collection.
#1 Best Overall
How the MDM2–p53 experiment worked
Researchers made a mirror-image version of the target
MDM2 negatively regulates p53, a tumor-suppressor protein. The team focused on the MDM2 p53-binding domain, residues 25–109, and chemically synthesized its mirror-image form, D-MDM2. They checked the handedness-specific binding behavior using surface plasmon resonance (SPR): the synthetic proteins bound corresponding mirror-image p53 peptides with high affinity, while mismatched handedness showed practically nil binding in those experiments.
They screened an existing collection
The researchers used chemical-array screening to test 22,293 compounds from RIKEN NPDepo, a collection containing natural products and derivatives. They reported 43 initial selective binding hits. In follow-up competitive binding assays, four compounds showed inhibitory activity against the natural L-MDM2–L-p53 interaction, the mirror-image D-MDM2–D-p53 interaction, or both.
They synthesized the selected mirror-image hit
One hit, NP843, is a chiral α-tocopherol derivative. It selectively inhibited the D-MDM2–D-p53 interaction, with a reported IC50 of 6.5 ± 0.5 μM. The researchers then synthesized its mirror-image enantiomer, ent-NP843. In a biochemical assay, ent-NP843 inhibited the natural L-MDM2–L-p53 interaction with a reported IC50 of 7.6 ± 1.9 μM.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →These IC50 values describe concentrations measured in the study’s assays; they are not evidence of effectiveness in animals or people. The results establish that the screening strategy produced a biochemical hit against the natural target, not that the compound can treat cancer.
What the mirror-image strategy changes—and what it does not
| Question | Direct screening of natural compounds | Mirror-image screening strategy |
|---|---|---|
| What is screened? | Available compounds against the natural target. | Available compounds against a synthesized mirror-image target. |
| What must be synthesized? | No mirror-image target is needed for ordinary direct screening. | A mirror-image target protein is needed; selected mirror-image hits must also be synthesized for tests against the natural target. |
| What chemical space can be explored? | The compounds physically available for screening. | Potentially, mirror-image counterparts of chiral compounds can be explored indirectly without synthesizing the whole mirror-image collection up front. |
| What did this study validate? | Not a comparison performed by the study. | Binding and competitive inhibition in biochemical assays for the MDM2–p53 system. |
| Was a time or cost advantage measured? | Not stated in the study. | Not stated in the study; reduced synthesis burden is a proposed advantage, not a quantified result. |
The approach shifts where synthesis effort is spent; it does not eliminate chemical synthesis or guarantee that a useful compound will emerge. In this demonstration, researchers synthesized D-MDM2 and one mirror-image hit, rather than preparing a complete mirror-image library. Whether the strategy can be applied to another target depends on access to the corresponding mirror-image biomolecule.
Why stereochemistry and molecular structure mattered
The follow-up work showed that activity depended on detailed molecular structure, not simply on making an opposite-handed copy. The stereochemistry at a tetrasubstituted carbon in the chromane scaffold mattered. In the tested derivatives, shortening the side chain from its three-isoprene-unit length eliminated inhibitory activity. Those findings make precise synthesis and follow-up testing central to the method: a candidate’s mirror-image form must retain the structural features needed for activity against the natural target.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What the 2016 result does—and does not—show
- It shows: synthetic D-MDM2 could serve as a screening proxy, and selected mirror-image compounds could then be tested against natural MDM2.
- It shows: NP843 and synthesized ent-NP843 inhibited their respective MDM2–p53 interactions in biochemical assays, with the reported assay-specific IC50 values.
- It does not show: that NP843 or ent-NP843 is an approved, validated, or clinically effective medicine, or that either treats cancer.
- It leaves open: how broadly the approach will yield leads, how accessible mirror-image proteins will be for other targets, and whether enough mirror-image compound can be produced for efficacy and safety evaluation in humans.
When the work was reported in 2016, Brian Cox, a chemical synthesis and drug discovery researcher at the University of Sussex, called it “a very exciting approach, assuming technologies can provide the proteins for screening.” That was a period assessment of the approach, not evidence of later clinical progress.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →The primary study is Taro Noguchi et al., “Screening of a virtual mirror-image library of natural products,” Chemical Communications 52 (2016), 7653–7656, first published May 11, 2016. Read the paper at the Royal Society of Chemistry. The contemporary report and expert comment appeared in Chemistry World on June 10, 2016: Mirror-image trick yields real hits from a virtual chemical library.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
